Shire announced that the Food and Drug Administration (FDA) has approved Cuvitru (immune globulin subcutaneous [human]) 20% solution for the treatment of primary immunodeficiency in patients aged ≥2 ...
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of CUVITRU™ [Immune Globulin ...
Shire Announces Completion of Decentralized Procedure in Europe for Immunoglobulin Treatment Cuvitru
With the addition of Cuvitru following the completion of the combination with Baxalta, Shire has the broadest immunoglobulin (IG) portfolio with intravenous, conventional and subcutaneous treatment ...
FRISCO, Texas--(BUSINESS WIRE)--#ComplexCare--Soleo Health, an innovative leader and national provider of complex specialty pharmacy services, announced today it has been chosen as one of a select few ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results